Life Science Investing Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference
Life Science Investing Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis
Life Science Investing Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference
Nine Mile Metals Announces Certified High-Grade Assay Results up to 15.00% Copper from the Wedge Project, Bathurst, New Brunswick
Apollo Silver Announces $2.5 Million Upsize to Previously Announced Financing to Allow for Insider Participation
